1. Home
  2. CELU vs ESLA Comparison

CELU vs ESLA Comparison

Compare CELU & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$1.57

Market Cap

50.7M

Sector

Health Care

ML Signal

HOLD

Logo Estrella Immunopharma Inc.

ESLA

Estrella Immunopharma Inc.

HOLD

Current Price

$1.79

Market Cap

48.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CELU
ESLA
Founded
2016
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.7M
48.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CELU
ESLA
Price
$1.57
$1.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$16.00
AVG Volume (30 Days)
62.5K
176.7K
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$40,578,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$76.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$0.73
52 Week High
$4.35
$3.15

Technical Indicators

Market Signals
Indicator
CELU
ESLA
Relative Strength Index (RSI) 32.57 49.56
Support Level $1.62 $1.67
Resistance Level $2.01 $2.16
Average True Range (ATR) 0.12 0.28
MACD -0.03 0.00
Stochastic Oscillator 1.37 54.67

Price Performance

Historical Comparison
CELU
ESLA

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

About ESLA Estrella Immunopharma Inc.

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Share on Social Networks: